ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY
March 12, 2024 07:30 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Company”) ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY Companies to combine proprietary...
Arecor: Business Update
July 20, 2023 07:00 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Group”) BUSINESS UPDATE Strong pipeline of revenue-generating collaborations with major pharmaceutical and biotech companies with further deals anticipated...
ARECOR PRESENTS FULL DATA FROM POSITIVE PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES AT ATTD MEETING
April 28, 2022 07:00 ET
|
Arecor Therapeutics plc
ARECOR PRESENTS FULL DATA FROM POSITIVE PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES AT ATTD MEETING Demonstrates best-in-class potential for effective...
ARECOR GRANTED KEY U.S. PATENT PROTECTING PROPRIETARY INSULIN PRODUCTS
March 23, 2022 08:00 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Group”) ARECOR GRANTED KEY U.S. PATENT PROTECTING PROPRIETARY INSULIN PRODUCTS Further strengthens the Company’s extensive patent portfolio protecting its...
BUSINESS UPDATE
January 20, 2022 07:01 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor”, the “Company” or the “Group”) BUSINESS UPDATEMomentum continues across partnered and proprietary portfolio Cambridge, UK, 20 January 2022: Arecor Therapeutics plc...
ARECOR ANNOUNCES AN EXCLUSIVE FORMULATION STUDY COLLABORATION WITH A LEADING GLOBAL MEDICAL PRODUCTS COMPANY TO DEVELOP A STABLE READY TO ADMINISTER PRODUCT
November 01, 2021 07:00 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Group”) ARECOR ANNOUNCES AN EXCLUSIVE FORMULATION STUDY COLLABORATION WITHA LEADING GLOBAL MEDICAL PRODUCTS COMPANY TO DEVELOP A STABLE READY TO ADMINISTER...